Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aldeyra Therapeutics Inc.

www.aldeyra.com

Latest From Aldeyra Therapeutics Inc.

Mixed Early Phase III Results With Aldeyra’s First-In-Class Dry Eye Candidate

The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.

Ophthalmic Clinical Trials

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances

In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.

Deals Financing

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies

Aldeyra One Step Closer To Joint Treatment For Allergic Conjunctivitis, Dry Eye Disease

With Phase III programs on similar timelines, Aldeyra hopes it may be able to file for both indications concurrently for its aldehyde trap candidate reproxalap.

Ophthalmic Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Neuron Systems Inc.
  • Aldexa Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aldeyra Therapeutics Inc.
  • Senior Management
  • Todd C Brady, MD, PhD, Pres. & CEO
    Joshua Reed, CFO
    David J Clark, MD, CMO
  • Contact Info
  • Aldeyra Therapeutics Inc.
    Phone: (781) 761-4904
    131 Hartwell Ave.
    Lexington, MA 02421
    USA
UsernamePublicRestriction

Register